Who is suitable for ponatinib?

Ponatinib (Ponatinib) is an oral third-generation tyrosine kinase inhibitor (TKI), mainly used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL) patients, especially those who are resistant to BCR-ABL gene mutations. It can inhibit multiple drug-resistant mutations including T315I, thereby providing new treatment options for patients who fail standard TKI treatments.

Chronic myeloid leukemia (CML) patients are the main candidates for ponatinib. For patients who are resistant or intolerant to first- and second-generation TKIs such as imatinib, dasatinib or nilotinib, ponatinib can be used as a later-line treatment option. Especially patients with T315I mutations, which are highly resistant to most TKIs, and ponatinib can effectively inhibit mutant BCR-ABL and improve hematological and molecular response rates.

Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) are also candidates for ponatinib. For treatment-naïve or relapsed/refractory Ph+ ALL patients, especially those who fail to respond to frontline TKI treatment or develop drug-resistant mutations, ponatinib can provide an effective targeted therapy option to help improve disease control and prolong progression-free survival. Clinical studies have shown that ponatinib can significantly improve the complete response rate and molecular response rate in Ph+ ALL patients.

For patients with multi-mutation resistance or special high-risk patients, such as BCR-ABL multiple mutations combined with T315I mutations CML patients, ponatinib also shows unique advantages. Such patients often have limited response to traditional TKIs and have rapid disease progression. Ponatinib can be used as a key salvage treatment. At the same time, doctors will make individual dosage adjustments based on the patient's cardiovascular risk and previous medication history to ensure a balance between efficacy and safety.

Reference link:https://www.drugs.com